Author's response to reviews

Title: Prescriber and patient-oriented behavioural interventions to improve use of malaria rapid diagnostic tests in Tanzania: facility-based cluster randomised trial

Authors:

Bonnie Cundill (bonnie.cundill@lshtm.ac.uk)
Hilda Mbakilwa (tufuwage@hotmail.com)
Clare I.R. Chandler (clare.chandler@lshtm.ac.uk)
George Mtove (mtoveq2002@gmail.com)
Frank Mtei (mailfrankmt@yahoo.com)
Annie Willetts (awilletts44@gmail.com)
Emily Foster (emilyfoster@doctors.org.uk)
Florida Muro (floridajm@yahoo.com)
Rahim Mwinyishehe (rahimumohamedi@yahoo.com)
Renata Mandike (renata@nmcp.go.tz)
Raimos Olomi (raimosolomi@yahoo.com)
Christopher J.M. Whitty (christopher.whitty@lshtm.ac.uk)
Hugh Reyburn (hugh.reyburn@lshtm.ac.uk)

Version: 4 Date: 7 April 2015

Author's response to reviews: see over
Dear Dr Lin Lee,

Response to Comments by Reviewers

Re: Prescriber and patient-oriented behavioural interventions to improve use of malaria rapid diagnostic tests in Tanzania: facility-based cluster randomised trial

We would like to thank the reviewers for their further review of our manuscript, in particular the interesting point made by Reviewer 2.

In light of the reviewers comment we would like to edit the second last sentence in the first paragraph of the discussion on page 17 to indicate that overtreatment could result in exposure of infections to the longer acting partner drug. We agree with the reviewer that there is less concern over shorter acting drugs such as artemether.

Unfortunately, I am currently out of the country and do not have access to a Word version of the manuscript under review to be able to edit page 17 of the manuscript accordingly. I would therefore be very grateful if you were able to consider the current version of the manuscript for publication with the following revision to the discussion:

Replace

"Near-zero overdiagnosis brings considerable gains that will become increasingly important if artemisinin resistance spreads to Africa."

with
"Near zero overdiagnosis brings considerable gains that will become increasingly important if resistance to ACTs spreads as infections occurring in the weeks following unnecessary treatment may be exposed to sub-therapeutic drug levels, particularly relevant to the longer acting ACT partner drugs such as piperaquine."

The remainder of the manuscript, tables, figures and appendices remain the same as the latest version that is currently uploaded. I will be back in the UK on the 14th April and will be able to make the revision and upload a revised version of the manuscript at this time.

Yours sincerely

Bonnie Cundill
For the authors